Company / Working Capital
BridgeBio Oncology Therapeutics, Inc. Working Capital History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.8M
FY2024
5-year range
$1.8M / $1.8M
FY2024-FY2024
Trend
-
vs FY2023
Sector context
#207 of 213
Health Care
What the data says
Among 213 Health Care companies, BridgeBio Oncology Therapeutics, Inc. is in the bottom 3% for working capital.
Based on SEC 10-K filings.
$2M in FY2024.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company $1.8M Sector average $934.6M
▼
-99.8% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.8M | - |
| FY2023 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026